RVMD
REVOLUTION MEDICINES INCData as of 2026 Q2 (06-30) · 13F snapshot
Summary
REVOLUTION MEDICINES INC (RVMD) is held as common stock by 7 tracked hedge-fund managers, with a combined reported value of ~$2.41B; the largest are Baker Bros. Advisors, Ken Griffin, Stanley Druckenmiller. 4 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 1 new, 3 added, 3 trimmed, 2 closed. 5 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Mixed
Common-stock holders74 also report options
Congress trades5
Price$201.74vs quarter-end+7.72%
Sectors0
This quarter's moves
Top holderBaker Bros. AdvisorsNew1
Added3
Trimmed / sold5
Common-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
Value $2.14B10.8% of portfolio11,443,3572026 Q2
Value $74.83M1.7% of portfolio399,5872026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Baker Bros. Advisors | $2.14B | 10.8% | Add |
| Stanley Druckenmiller | $74.83M | 1.7% | Add |
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $85.19M— of portfolio454,9002026 Q2
Value $31.39M— of portfolio167,6002026 Q2
Value $8.35M— of portfolio44,6002026 Q2
Value $3.80M— of portfolio20,3002026 Q2
Value $2.77M— of portfolio14,8002026 Q2
Value $2.57M— of portfolio13,7002026 Q2
Value $430.7K— of portfolio2,3002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $85.19M | — | — |
| Ken GriffinPUT | $31.39M | — | — |
| Izzy EnglanderCALL | $8.35M | — | — |
| Steven CohenCALL | $3.80M | — | — |
| Paul Tudor JonesPUT | $2.77M | — | — |
| Paul Tudor JonesCALL | $2.57M | — | — |
| Izzy EnglanderPUT | $430.7K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.